Wall Street Zen upgraded shares of Illumina (NASDAQ:ILMN – Free Report) from a hold rating to a buy rating in a research note released on Saturday.
A number of other equities analysts also recently issued reports on ILMN. Evercore reiterated an “outperform” rating on shares of Illumina in a research report on Monday, July 6th. Barclays boosted their price objective on Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a research report on Friday. Weiss Ratings raised Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Royal Bank Of Canada lifted their price target on shares of Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a research note on Friday. Finally, Piper Sandler boosted their price target on shares of Illumina from $170.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday, July 1st. Eight analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $188.40.
View Our Latest Stock Analysis on ILMN
Illumina Trading Down 3.4%
Illumina (NASDAQ:ILMN – Get Free Report) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same period in the prior year, the company posted $1.19 EPS. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts predict that Illumina will post 5.37 earnings per share for the current fiscal year.
Insider Transactions at Illumina
In other news, SVP Patricia Leckman sold 783 shares of the firm’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the transaction, the senior vice president directly owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. This trade represents a 3.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 1,500 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $150.10, for a total transaction of $225,150.00. Following the transaction, the chief accounting officer owned 14,946 shares in the company, valued at $2,243,394.60. The trade was a 9.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 1,004,384 shares of company stock valued at $155,833,908. Company insiders own 2.90% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. WCM Investment Management LLC raised its stake in Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after purchasing an additional 1,851,848 shares during the period. Invesco Ltd. boosted its holdings in Illumina by 97.0% in the 4th quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock valued at $360,426,000 after purchasing an additional 1,352,731 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Illumina by 30.3% in the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after buying an additional 1,028,099 shares during the period. Morgan Stanley grew its stake in shares of Illumina by 66.0% in the 4th quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company’s stock valued at $331,710,000 after buying an additional 1,005,474 shares during the period. Finally, Vaughan Nelson Investment Management L.P. acquired a new stake in shares of Illumina during the 1st quarter worth approximately $106,462,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.
More Illumina News
Here are the key news stories impacting Illumina this week:
- Positive Sentiment: Raised revenue outlook and clinical-sequencing demand support the stock. Illumina reported second-quarter revenue of $1.159 billion, up from $1.059 billion a year earlier, and raised its 2026 revenue forecast to $4.60 billion-$4.64 billion. Management’s focus on clinical sequencing and multi-omics is reinforcing expectations for continued growth. Why Illumina Is Up After Raising 2026 Revenue Outlook
- Positive Sentiment: Analysts raised their valuation expectations. Piper Sandler reaffirmed its “overweight” rating and increased its price target to $225 from $200. Other recent reports cited price targets of $210 and $230, indicating that some analysts see additional upside despite the stock’s recent rally. Piper Sandler Rating Report Illumina Price Target Raised to $210 Illumina Price Target Raised to $230
- Neutral Sentiment: Momentum is strong, but investors are questioning how much upside remains. ILMN reached a fresh 52-week high after more than doubling over the past year. The move reflects improving fundamentals, but the elevated share price increases sensitivity to any execution or guidance disappointment. Illumina Hits Fresh High
- Negative Sentiment: Valuation and cash-flow concerns could weigh on returns. One analysis estimates the shares may be approximately 19% overvalued, while another notes that market multiples appear expensive even though a discounted-cash-flow model suggests potential upside. Broader concerns include whether strong cash generation will translate into efficient spending and sustained growth. Illumina Could Be Overvalued Cash-Producing Stocks That Concern Us
- Negative Sentiment: An insider sold shares. Scott M. Davies sold 615 shares worth $123,000 under a pre-arranged Rule 10b5-1 plan. The sale was relatively small and leaves him with 20,338 shares, but it is still a modest negative signal for sentiment.
About Illumina
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Featured Articles
- Five stocks we like better than Illumina
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
